The Oncology Institute, Inc. (TOI) Stock Analysis
Range Bound setup · Inst Constrain edge
Healthcare · Medical Care Facilities
Sell if holding. Engine safety override at $5.28: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 6.1/10 and A.R:R 1.6:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality.
The Oncology Institute, Inc., an oncology company, provides various oncology services in the United States. It operates through three segments: Specialty pharmacy, Patient Services, and Clinical Trials & Other. The company offers physician services, in-house infusion, in-house... Read more
Sell if holding. Engine safety override at $5.28: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 6.1/10 and A.R:R 1.6:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality. Chart setup: RSI 54 mid-range, Bollinger mid-band. Score 6.1/10, moderate confidence.
Passes 8/8 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 37d clear, semi cycle peak clear, materials cycle peak clear). Suitability: aggressive.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker·1 ceiling hit
Unprofitable operations — net margin -8.0%. Quality floor flags this regardless of sector context.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $5.28: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 6.1/10 and A.R:R 1.6:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality. Chart setup: RSI 54 mid-range, Bollinger mid-band. Prior stop was $4.91. Score 6.1/10, moderate confidence.
Take-profit target: $6.59 (+24.8% upside). Prior stop was $4.91. Stop-loss: $4.91.
Quality below floor (1.6 < 4.0); Value-trap signals (3/5): Margin compression (op margin -39.8%), Material insider selling (3 sells, 0.04% of cap), Negative free cash flow.
The Oncology Institute, Inc. trades at a P/E of N/A (forward -33.0). TrendMatrix value score: 8.4/10. Verdict: Sell.
8 analysts cover TOI with a consensus score of 4.1/5. Average price target: $8.
What does The Oncology Institute, Inc. do?The Oncology Institute, Inc., an oncology company, provides various oncology services in the United States. It operates...
The Oncology Institute, Inc., an oncology company, provides various oncology services in the United States. It operates through three segments: Specialty pharmacy, Patient Services, and Clinical Trials & Other. The company offers physician services, in-house infusion, in-house specialty pharmacy, clinical trials, radiation therapy, and outpatient blood product transfusion services, as well as educational seminars, support groups, counseling services, and 24/7 patient assistance and support services. It also manages clinical trials and palliative care programs; operates combined community clinics and infusion suites; and operates a specialty pharmacy that includes both in-office and mail-order dispensing for complementary oral and self-injectable medications taken by patients concurrent with their in-office cancer therapies. It serves adult and senior cancer patients. The Oncology Institute, Inc. was founded in 2007 and is headquartered in Cerritos, California.